Development of upstream bioprocesses using vero cells to produce viral vectors and vaccines

Author(s): Alex Quill

For the purpose of creating viral vectors and vaccines, the Vero cell line is thought to be the most often employed continuous cell line. It is the first cell line in history to receive WHO approval for use in the creation of human vaccines. The literature contains extensive experimental data on the generation of several viruses utilising the Vero cell line. However, the micro-carrier technology is used in the vast majority of these procedures. Although this technology has been developed for the mass production of viral vaccines, it is still quite labor-intensive and complicated. Additionally, scale-up is still challenging and is constrained by the carriers’ provided surface area. It is crucial to continue to expand the Vero cell platform by utilising cutting-edge bioprocess technologies in order to get around these and other issues as well as to establish more effective manufacturing procedures. Advanced and scalable platform technologies could offer more effective and affordable ways to address the worldwide need for vaccines, particularly in situations like the present COVID-19 pandemic. In order to evaluate recent developments in bioprocess development, we analyse the current literature on Vero cell bioprocess development for the creation of viral vectors and vaccines in this article. By utilising recent advancements in the field of cell culture engineering, we critically highlight the necessity for additional research initiatives and outline obstacles to enhance the Vero cell platform [1-5].